LYON - Theranexus, a biopharmaceutical company innovating the treatment of neurological diseases and pioneering the development of drug candidates modulating the interaction between neurons and glial cells, has announced the success of its Phase II trial for drug candidate THN102 for Parkinson's disease.

Seventy-five Parkinson's patients with debilitating, excessive daytime sleepiness (EDS) were recruited in Europe and the United States. The study was a double-blind, placebo-controlled, crossover trial with a one-week washout period between each successive two-week treatment period. The treatments were given in random order and consisted of: THN102 200mg modafinil/2mg flecainide, THN102 200mg modafinil/18mg flecainide, or a placebo.

THN102 met the primary efficacy endpoint and significantly increased the proportion of patients no longer suffering from daytime sleepiness for the duration of the treatment

The trial demonstrated the efficacy of THN102 in doses of THN102 200mg modafinil/2mg flecainide ('THN102-200/2'), with significant superiority over the placebo in reducing EDS measured using the Epworth Sleepiness Scale (ESS - the most widely used sleepiness scale, ranging from 0 to 24). The ESS score improved by 3.9 points in patients after treatment with THN102-200/2. This improvement is highly significant (p=0.01) compared with that achieved by the placebo (2.4 points).

The proportion of patients no longer presenting excessive daytime sleepiness for the duration of the treatment (commonly defined as ESS

(C) 2020 Electronic News Publishing, source ENP Newswire